Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.
Alternative Splicing
/ genetics
Animals
B7-H1 Antigen
/ antagonists & inhibitors
Cell Proliferation
Conserved Sequence
/ genetics
Evolution, Molecular
Exons
/ genetics
HEK293 Cells
Hominidae
/ genetics
Humans
Immunosuppression Therapy
Mice, Inbred C57BL
Protein Domains
Retroelements
/ genetics
Solubility
LINE
PD-L1
chromosomes
gene expression
human
immunology
inflammation
receptor antagonist
retroelement
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
16
07
2019
accepted:
13
11
2019
pubmed:
16
11
2019
medline:
12
5
2020
entrez:
16
11
2019
Statut:
epublish
Résumé
Immune regulation is a finely balanced process of positive and negative signals. PD-L1 and its receptor PD-1 are critical regulators of autoimmune, antiviral and antitumoural T cell responses. Although the function of its predominant membrane-bound form is well established, the source and biological activity of soluble PD-L1 (sPD-L1) remain incompletely understood. Here, we show that sPD-L1 in human healthy tissues and tumours is produced by exaptation of an intronic
Identifiants
pubmed: 31729316
doi: 10.7554/eLife.50256
pii: 50256
pmc: PMC6877088
doi:
pii:
Substances chimiques
B7-H1 Antigen
0
Retroelements
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome
ID : 102898/B/13/Z
Pays : International
Organisme : Francis Crick Institute
ID : 10099
Pays : International
Informations de copyright
© 2019, Ng et al.
Déclaration de conflit d'intérêts
KN, JA, GY, EO, SP, IK, GK No competing interests declared
Références
Nat Rev Immunol. 2016 Apr;16(4):207-19
pubmed: 27026073
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
J Exp Med. 2019 Apr 1;216(4):982-1000
pubmed: 30872362
Cell. 2012 May 11;149(4):740-52
pubmed: 22579280
Curr Top Microbiol Immunol. 2017;410:75-97
pubmed: 28929192
Leukemia. 2007 Dec;21(12):2463-9
pubmed: 17728785
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
Nat Biotechnol. 2011 May 15;29(7):644-52
pubmed: 21572440
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
Cell. 2008 Oct 3;135(1):23-35
pubmed: 18854152
Theory Biosci. 2012 Dec;131(4):281-5
pubmed: 22872506
Int Rev Immunol. 1998;16(5-6):457-99
pubmed: 9646173
Bioinformatics. 2013 Oct 1;29(19):2487-9
pubmed: 23842809
Blood. 2005 Oct 15;106(8):2781-9
pubmed: 15998834
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
J Immunol. 2014 Feb 15;192(4):1491-501
pubmed: 24403533
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Nat Rev Immunol. 2015 Mar;15(3):172-84
pubmed: 25712152
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Cancer Immunol Immunother. 2019 Mar;68(3):407-420
pubmed: 30564890
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Mediators Inflamm. 2013;2013:165974
pubmed: 23853427
Immunol Lett. 2012 Feb 29;142(1-2):78-82
pubmed: 22138406
Nature. 2011 Mar 17;471(7338):377-81
pubmed: 21368758
Biochem Biophys Res Commun. 2010 Aug 27;399(3):384-90
pubmed: 20673754
Sci Rep. 2016 Jun 17;6:28083
pubmed: 27312428
J Cell Sci. 2013 Dec 15;126(Pt 24):5553-65
pubmed: 24105262
Front Microbiol. 2017 Dec 12;8:2489
pubmed: 29312197
Nat Rev Genet. 2012 Mar 16;13(4):283-96
pubmed: 22421730
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
Cell Immunol. 2005 Jun;235(2):109-16
pubmed: 16171790
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Mob DNA. 2016 Dec 1;7:24
pubmed: 27980689
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
Scand J Immunol. 2007 Nov;66(5):529-37
pubmed: 17953528
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Cancer Immunol Immunother. 2019 Mar;68(3):421-432
pubmed: 30564891
Eur J Immunol. 1999 Nov;29(11):3596-602
pubmed: 10556814
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Oncotarget. 2015 Dec 1;6(38):41228-36
pubmed: 26515600
Crit Rev Immunol. 2017;37(2-6):249-259
pubmed: 29773022
J Exp Med. 2019 Jul 1;216(7):1525-1541
pubmed: 31123083
Sci Rep. 2017 Feb 16;7:42687
pubmed: 28202921
Sci Adv. 2018 Mar 07;4(3):eaar2766
pubmed: 29532035
Genome Res. 2019 Oct;29(10):1578-1590
pubmed: 31537638
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
FEBS J. 2018 Mar;285(5):809-827
pubmed: 29032605
Anticancer Res. 2018 Oct;38(10):5739-5745
pubmed: 30275195
J Exp Med. 2003 Sep 15;198(6):851-62
pubmed: 12975453
PLoS One. 2014 Oct 14;9(10):e109760
pubmed: 25314013
Nat Commun. 2018 Apr 30;9(1):1716
pubmed: 29712909